Rani Therapeutics Holdings Inc. (RANI) Insider Trading

Last 12 months

Insiders bought $1.32M and sold $301 on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan.

Net open-market

+$1.32M

3 buys · 1 sale

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

2 / 1

executives and directors

Last open-market buy

Jul 2026

Jul 21, 2026

Get an email when RANI's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Jul 21	Mir A Imran Director	Bought	36,000	$0.69	$25k	0.1%	Form 4
Jul 17	Talat Imran Chief Executive Officer	Bought	35,000	$0.72	$25k	8.1%	Form 4
Mar 27	Alireza Javadi Chief Technical Officer	SoldNo plan	386	$0.78	$301	4.0%	Form 4
Oct 23, 2025	Mir A Imran Director	Bought	2,083,334	$0.61	$1.27M	9.2%	Form 4
Oct 20, 2025 – Oct 21, 2025	South Cone Investments Limited Partnership Large holder	SoldNo plan 2 parts	5,923,000	$2.65 average	$15.7M	71%	Form 4
Dec 27, 2024	Talat Imran Chief Executive Officer	SoldNo plan	8,014	$1.41	$11k	1.8%	Form 4
Dec 13, 2024	Kate McKinley Chief Business Officer	Bought	17,960	$1.67	$30k	New	Form 4
Dec 9, 2024	Talat Imran Chief Executive Officer	Bought	10,296	$1.94	$20k	2.1%	Form 4

Jul 21
Mir A Imran
Director · bought 36,000 at $0.69
$25k
0.1% of stake
Jul 17
Talat Imran
Chief Executive Officer · bought 35,000 at $0.72
$25k
8.1% of stake
Mar 27No plan
Alireza Javadi
Chief Technical Officer · sold 386 at $0.78
$301
4.0% of stake
Oct 23, 2025
Mir A Imran
Director · bought 2,083,334 at $0.61
$1.27M
9.2% of stake
Oct 20, 2025 – Oct 21, 2025No plan
South Cone Investments Limited Partnership
Large holder · sold 5,923,000 at avg $2.65
$15.7M
71% of stake
Dec 27, 2024No plan
Talat Imran
Chief Executive Officer · sold 8,014 at $1.41
$11k
1.8% of stake
Dec 13, 2024
Kate McKinley
Chief Business Officer · bought 17,960 at $1.67
$30k
New position
Dec 9, 2024
Talat Imran
Chief Executive Officer · bought 10,296 at $1.94
$20k
2.1% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch RANI, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: Pharmaceutical Preparations

INMInMed Pharmaceuticals Inc.

PCYNProcyon Corporation

BOLTBolt Biotherapeutics Inc.

KYNBKyntra Bio, Inc.

ENSCEnsysce Biosciences Inc.

ATAIAtaiBeckley Inc.

PRPHProPhase Labs Inc.

TRDAEntrada Therapeutics Inc.

Spot a number that looks wrong? Check it in RANI's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing RANI

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.